Page last updated: 2024-12-05

acridines

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Acridines are a class of heterocyclic organic compounds that have a tricyclic ring system consisting of two benzene rings fused to a pyridine ring. They are known for their diverse biological activities and have been extensively studied for their potential applications in medicine, agriculture, and materials science. Acridines are commonly synthesized through various methods, including the Skraup synthesis, the Friedländer synthesis, and the Pictet-Spengler reaction. These compounds exhibit a wide range of biological effects, including antibacterial, antifungal, anti-inflammatory, and anticancer activities. Their importance lies in their ability to interact with DNA and other biomolecules, leading to a variety of pharmacological effects. Acridines are studied extensively due to their potential as therapeutic agents, as well as their ability to act as fluorescent probes and chemosensors. The development of new acridine derivatives with improved efficacy and selectivity is an ongoing area of research.'
```

Acridines: Compounds that include the structure of acridine. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

acridine : A polycyclic heteroarene that is anthracene in which one of the central CH groups is replaced by a nitrogen atom. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9215
CHEMBL ID39677
CHEBI ID36420
SCHEMBL ID12474214
SCHEMBL ID8339
SCHEMBL ID6265106
MeSH IDM0000249

Synonyms (61)

Synonym
akridin
2,3,5,6-dibenzopyridine
CHEBI:36420 ,
un2713
dibenzo(b,e)pyridine
brn 0120200
benzo(b)quinoline
hsdb 634
nsc 3408
akridin [czech]
ccris 1636
ai3-15279
einecs 205-971-6
coal tar pitch volatiles: acridine
9-azaanthracene
acridine
benzo[b]quinoline
260-94-6
10-azaanthracene
nsc3408
wln: t c666 bnj
nsc-3408
acrydine
dibenzo[b,e]pyridine
2,3-benzoquinoline
AC-907/21098007
UPCMLD-DP077:001
inchi=1/c13h9n/c1-3-7-12-10(5-1)9-11-6-2-4-8-13(11)14-12/h1-9
acridine, 97%
UPCMLD-DP077
NCGC00161635-01
acridines
A0129
A0294
CHEMBL39677
AKOS001568550
NCGC00161635-02
5-20-08-00199 (beilstein handbook reference)
acridine [un2713] [poison]
unii-42ni1p5q1x
42ni1p5q1x ,
C20141
A818165
benzoquinolinylidene
FT-0621864
acridine [mi]
SCHEMBL12474214
acridine acid
SCHEMBL8339
DTXSID8059766
un 2713
J-200084
SCHEMBL6265106
mfcd00005025
acridine, bioreagent, suitable for fluorescence, >=97.0% (hplc)
AS-42152
Q342713
AMY24990
bdbm50551545
EN300-21156
acridine (purified by sublimation)

Research Excerpts

Effects

Acridines have been used as chemotherapeutic agents against bacteria, protozoa and fungi. They now find important use as anticancer drugs.

ExcerptReferenceRelevance
"Acridines have been studied for several decades because of their numerous biological effects, especially anticancer activity. "( Subcellular localization of proflavine derivative and induction of oxidative stress--in vitro studies.
Cižeková, L; Grolmusová, A; Hunáková, L; Imrich, J; Ipóthová, Z; Janovec, L; Labudová, M; Paulíková, H, 2013
)
1.83
"Acridines have been used as chemotherapeutic agents against bacteria, protozoa and fungi, and they now find important use as anticancer drugs. "( Crystal structures of acridines complexed with nucleic acids.
Adams, A, 2002
)
2.07

Toxicity

ExcerptReferenceRelevance
" The 121-mumol/kg dose was well tolerated by mice, with sedation being the only obvious side effect and no significant alterations in blood biochemistry or haematological parameters being recorded."( Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse.
Cornford, EM; Evans, SM; Kestell, P; Paxton, JW; Robertson, IG; Young, D, 1992
)
0.28
" Toxic effects of the drug at high doses included nausea, diarrhoea and decreased levels of consciousness."( A phase I study of immunostimulation and toxicity in patients with colorectal carcinoma using the immunomodulator 3,6-bis(2-piperidinoethoxy) acridine trihydrochloride (CL 246738).
Dickinson, A; Halcrow, P; Hales, J; Harris, AL; Lawrence, GF; Lennard, TW; McDonald, M; Shenton, BK; Taylor, RM; Wolstencroft, R, 1989
)
0.28
" Based on these data, the no observable adverse effect level of acridine was judged to be 100 ppm or 12 mg/kg bw/day."( The subchronic toxicity of acridine in the rat.
Chu, I; Moir, D; Park, G; Poon, R; Valli, VE; Viau, A; Yagminas, A, 1997
)
0.3
" Neoamphimedine exhibited enhanced toxicity in top2 over-expressing yeast cells and was toxic in every mammalian cell line tested."( The anti-neoplastic and novel topoisomerase II-mediated cytotoxicity of neoamphimedine, a marine pyridoacridine.
Barrows, LR; Concepción, GP; Holden, JA; Ireland, CM; Marshall, KM; Matsumoto, SS; Tasdemir, D, 2003
)
0.32
" The adverse event profile was similar between groups; however, patients who received S-303 RBCs were significantly more likely to develop constipation and less likely to suffer supraventricular extrasystoles."( Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients.
Benjamin, RJ; Conlan, MG; Corash, L; Lin, JS; McCullough, J; Mintz, PD; Rizzo, RJ; Snyder, E; Spotnitz, WD; Wages, D; Wood, L, 2005
)
0.33
" These acridine dimers have demonstrated a narrow safe margin, as has adriamycin, but higher maximum tolerate dose (MTD) in comparison with that of adriamycin in ICR mice."( Linker-modified triamine-linked acridine dimers: synthesis and cytotoxicity properties in vitro and in vivo.
Chang, HO; Chang, LS; Chou, SY; Hsu, SC; Lee, YJ; Wang, SS; Yin, WK, 2007
)
0.34
" Effect concentrations expressed as soil pore-water concentrations were related to log K(ow), which indicated narcosis as the most probable mode of toxic action."( Toxicity of four nitrogen-heterocyclic polyaromatic hydrocarbons (NPAHs) to soil organisms.
Bezchlebová, J; Hofman, J; Kobetičová, K; Lána, J; Sochová, I, 2008
)
0.35
" We demonstrate that quinacrine caused a significant reduction of hPrP90-231 toxicity due to its binding to the fragment and the prevention of its conversion in a toxic isoform."( Efficacy of novel acridine derivatives in the inhibition of hPrP90-231 prion protein fragment toxicity.
Aceto, A; Boido, V; Canu, C; Chiovitti, K; Corsaro, A; Florio, T; Novelli, F; Paludi, D; Pino, A; Russo, C; Sparatore, A; Sparatore, F; Tasso, B; Thellung, S; Tonelli, M; Villa, V, 2011
)
0.37
" However, there are concerns regarding the initiation of possible NP-mediated adverse events in AD, thus demanding the use of precisely assembled nanoconstructs from biocompatible materials."( Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues.
Andrieux, K; Brambilla, D; Couvreur, P; Hashemi, SH; Le Droumaguet, B; Moghimi, SM; Nicolas, J; Wu, LP, 2011
)
0.37
"The aim of this study was to compare the toxic effects of selected two- and three-ringed PAHs (naphthalene, phenanthrene, and anthracene) and their N-heterocyclic analogs with one (quinoline, acridine, and phenanthridine) or two (quinoxaline, phenazine, and 1,10-phenanthroline) nitrogen atoms on the survival and reproduction of Enchytraeus crypticus in artificial soil."( Toxic effects of nine polycyclic aromatic compounds on Enchytraeus crypticus in artificial soil in relation to their properties.
Brezovský, J; Hofman, J; Kobetičová, K; Simek, Z, 2011
)
0.37
" Furthermore, a set of mass peaks could be identified as a specific biomarker for a single toxin treatment, so IC-MS demonstrates a new method for the distinction of toxic effects in fish cells."( Intact cell mass spectrometry as a rapid and specific tool for the differentiation of toxic effects in cell-based ecotoxicological test systems.
Frohme, M; Grienitz, D; Hollert, H; Kober, SL; Meyer-Alert, H, 2015
)
0.42
" The LD50 (lethal dose 50%) value in mice was estimated to be higher than 5000 mg/kg (intraperitoneally)."( Toxicity and Antitumor Activity of a Thiophene-Acridine Hybrid.
Andrade, C; Duarte, S; Farias, D; Ferreira, R; Lisboa, T; Lopes, AL; Magalhães, H; Medeiros, K; Moura, R; Reis, M; Ribeiro, J; Silva, D; Sobral, M, 2019
)
0.51

Pharmacokinetics

ExcerptReferenceRelevance
" studies, but the shape of the plasma concentration-time profile was considerably different, reflecting a 3-fold lower Cmax value (20."( Intraperitoneal administration of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in the mouse: bioavailability, pharmacokinetics and toxicity after a single dose.
Evans, SM; Paxton, JW; Robertson, IG; Young, D, 1992
)
0.28
") to find a pharmacodynamic basis for this insect's differential susceptibility to acridine at different life stages."( Pharmacodynamic behavior of [14C]acridine in the cricket Acheta domesticus (L.).
Maggart, EF; Walton, BT,
)
0.13
" Plasma samples were obtained for pharmacokinetic analysis in 17 patients."( Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
Adamson, PC; Arndt, C; Balis, FM; Berg, SL; Blaney, SM; Blatt, J; O'Brien, M; Poplack, DG, 1998
)
0.3
"We conclude that spectral analysis provides important pharmacokinetic information about radiolabeled anti-cancer drugs with relatively few model assumptions."( Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study.
Brock, CS; Cunningham, VJ; Harte, RJ; Jones, T; Matthews, JC; Meikle, SR; Price, P; Wells, P, 1998
)
0.3
" The pharmacokinetic results obtained here in mice have been used to facilitate the dose escalations during the Phase I trial and to determine pharmacokinetic drug exposure targets for its acute and sub-acute toxic effects."( Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.
Baker, LH; Foster, BJ; LoRusso, PM; Wiegand, RA, 1995
)
0.29
" The pharmacokinetic characteristics of doxorubicin in the presence or absence of GF120918 indicate a very minor overall effect of the modulator, except at the highest combined dose level (i."( Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.
Chandler, LH; de Bruijn, P; Jewell, RC; Loos, WJ; Nooter, K; Paul, EM; Planting, AS; Sparreboom, A; van der Burg, ME; van der Gaast, A; Verweij, J; Wissel, PS, 1999
)
0.3
" Pharmacokinetic studies to determine PZA plasma concentrations were performed."( A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer.
Budd, GT; Bukowski, RM; Ganapathi, R; McLain, D; Olencki, T; Peereboom, D; Pelley, R; Rybicki, L; Wood, L, 2000
)
0.31
" Significantly higher AUC, SUV, and Cmax were observed in tumors in phase I studies."( Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography.
Aboagye, EO; Bleehen, N; Brady, F; Brown, GD; Connors, T; Harte, RJ; Jones, T; Luthra, SK; Matthews, JC; Osman, S; Price, PM; Saleem, A, 2001
)
0.31
" However, to date, a detailed description of the preclinical pharmacokinetic properties of GF120918A has not been published."( Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, an
Azzarano, LM; Ward, KW, 2004
)
0.32
" Results of pharmacokinetic modeling were consistent with the hypothesis that GF120918 inhibited a [3H]DPDPE basolateral excretion mechanism."( Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems.
Brouwer, KL; Hoffmaster, KA; Pollack, GM; Zamek-Gliszczynski, MJ, 2004
)
0.32
" The objective of the present study was to evaluate the potential for in vivo pharmacokinetic interactions by comparing the pharmacokinetics of topotecan (a model BCRP substrate) after oral administration of 2 mg/kg topotecan with and without different doses of the flavonoids chrysin or 7,8-benzoflavone (BF) in rats and mdr1a/1b (-/-) mice."( Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
Morris, ME; Sagawa, K; Wang, X; Zhang, S, 2005
)
0.33
" The values of the pharmacodynamic parameters E(0), E(max), EC(50) and Hill factor were 45."( Influence of biophase distribution and P-glycoprotein interaction on pharmacokinetic-pharmacodynamic modelling of the effects of morphine on the EEG.
Bouw, MR; Danhof, M; de Lange, EC; de Mik, D; Freijer, J; Groenendaal, D, 2007
)
0.34
"This study aimed to evaluate the utility of plasma pharmacokinetic analyses of anti-cancer agents from data obtained during positron emission tomography (PET) oncology studies of radiolabelled anti-cancer agents."( Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes.
Aboagye, EO; Matthews, JC; Price, PM; Saleem, A, 2008
)
0.35
" Plasma pharmacokinetic parameters were estimated using model-dependent and model-independent methods."( Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes.
Aboagye, EO; Matthews, JC; Price, PM; Saleem, A, 2008
)
0.35
" However, drugs with half-lives longer than the sampling duration are inappropriate for PET plasma pharmacokinetic evaluation."( Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes.
Aboagye, EO; Matthews, JC; Price, PM; Saleem, A, 2008
)
0.35
" There were no significant differences between group CON and the other pretreatment groups in pharmacokinetic parameters taking both sexes into account."( The influence of modulation of P-glycoprotein and /or cytochrome P450 3A on the pharmacokinetics and pharmacodynamics of orally administered morphine in dogs.
Croubels, S; Gadeyne, C; Gasthuys, F; Polis, I; Schauvliege, S; Van der Heyden, S, 2011
)
0.37
"As part of a preclinical safety evaluation program, intravenous toxicity, safety pharmacology, toxicokinetic, and pharmacokinetic studies were conducted in rats and dogs with S-303 RBCs and S-300."( Preclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment.
Ciaravino, V; Corash, L; Mufti, N; North, A, 2011
)
0.37
" A simple physiologically-based pharmacokinetic model was developed to quantitatively determine the interplay between the individual transporters."( Understanding the interplay of drug transporters involved in the disposition of rosuvastatin in the isolated perfused rat liver using a physiologically-based pharmacokinetic model.
Birch, H; Hobbs, M; Kenworthy, K; Parker, C, 2012
)
0.38
"Plasma pharmacokinetic (PK) studies were conducted following administration of AR-67 lactone or carboxylate doses alone or after pre-dosing with inhibitors of the efflux transporters P-gp and Bcrp."( Pharmacokinetic modeling to assess factors affecting the oral bioavailability of the lactone and carboxylate forms of the lipophilic camptothecin analogue AR-67 in rats.
Adane, ED; Anderson, BD; Leggas, M; Liu, Z; Xiang, TX, 2012
)
0.38
" In Part II, there were no significant differences in Cmax, AUC0-tn or tmax between 4 mg single dose fasting group and fed group (p=0."( A single-center, randomized, open-label, dose-escalation study to evaluate the pharmacokinetics of tacrine analogue octahydrogenacridine succinate tablets in healthy Chinese subjects.
Cui, Y; Gu, J; Liang, Y; Wang, D; Xu, J; Zhang, D; Zhao, X, 2012
)
0.38
" The aim of this study was to investigate the potential pharmacokinetic interactions between Rh2 and the HIV protease inhibitor ritonavir."( Pharmacokinetic interactions between 20(S)-ginsenoside Rh2 and the HIV protease inhibitor ritonavir in vitro and in vivo.
Aa, JY; Cao, B; Ge, C; Gu, RR; Li, MJ; Liu, CX; Liu, LS; Ma, T; Mao, Y; Shi, J; Sun, RB; Wang, GJ; Wang, XW; Wu, XL; Xia, WJ; Xiao, WJ; Yu, XY; Zha, WB; Zheng, T; Zhou, J, 2013
)
0.39
" Pharmacokinetic modeling revealed that CLBL and CLBile represent alternative elimination routes with quantitatively similar contributions to the overall hepatocellular excretion of RSV in rat SCH under baseline conditions (WT SCH in the absence of GF120918) and also in human SCH."( Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes.
Brouwer, KL; Pfeifer, ND; Yang, K, 2013
)
0.39
" Besides, the simultaneous administration of elacridar and tariquidar did not significantly modify the pharmacokinetic parameters of loperamide."( Coadministration of P-glycoprotein modulators on loperamide pharmacokinetics and brain distribution.
Beduneau, A; Gromand, J; Lamprecht, A; Montesinos, RN; Moulari, B; Pellequer, Y, 2014
)
0.4
" Though P-gp-mediated efflux may contribute to the limited brain penetration of etamicastat, the low permeability along with the pharmacokinetic properties of etamicastat may be perceived as the main contributors for its peripheral selectivity, which is advantageous for a cardiovascular drug candidate."( Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat.
Bonifácio, MJ; Fernandes-Lopes, C; Igreja, B; Loureiro, AI; Pires, N; Soares-da-Silva, P; Wright, LC, 2015
)
0.42
" In vivo pharmacodynamic properties (parasite clearance time, parasite reduction ratio, dose and regimen determination) against multidrug resistant (MDR) rodent malaria parasite and toxicological parameters (median lethal dose, liver function test, kidney function test) were also investigated."( Pyrrolidine-Acridine hybrid in Artemisinin-based combination: a pharmacodynamic study.
Batra, S; Biswas, S; Chauhan, BS; Gunjan, S; Pandey, SK; Singh, S; Singh, SK; Srivastava, K; Tripathi, R, 2016
)
0.43
" Pharmacokinetic parameters were measured in naive mice."( Efficacy, metabolism and pharmacokinetics of Ro 15-5458, a forgotten schistosomicidal 9-acridanone hydrazone.
Caffrey, CR; Charman, SA; Dong, Y; El-Sakkary, N; Gangoiti, J; Häberli, C; Huang, J; Keiser, J; Momper, JD; Probst, A; Siegel, D; Skinner, DE; Ta, AP; Vennerstrom, JL; Vigneron, S, 2020
)
0.56
" The study focused on description of the pharmacokinetic behaviour of K1234, blood-brain barrier penetration, identification of the main in vitro and in vivo metabolites."( UHPLC-HRMS study of pharmacokinetics of a novel hybrid cholinesterase inhibitor K1234: A comparison between in silico, in vitro and in vivo data.
Hroch, M; Karasova-Zdarova, J; Korabecny, J; Mezeiova, E; Mzik, M; Pejchal, J; Sestak, V, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
"Glycine or DL-alpha-alanine potentiated the chemotherapeutic action of 3,6-diaminoacridinium without increasing its toxicity when these amino acids were combined with it simultaneously."( Potentiated chemotherapeutic activity of 3,6-diamino-10-methyl-acridinium by combination with glycine or DL-alpha-alanine on the Ehrlich carcinoma.
Osswald, H, 1975
)
0.25
" Intraamniotic Rivanol injection combined with oxytocin infusion seemed an effective and safe method for terminating second trimester pregnancies."( Induction of second trimester abortion by intraamniotic instillation of Rivanol (ethacridine) combined with oxytocin infusion.
Gardó, S; Nagy, M, 1990
)
0.28
"Induction of 2nd trimester abortion was studied by administration of the acridine derivative Rivanol in combination with an intravenous (iv) drip infusion of oxytocin or prostaglandin (PGF2alpha), alone or in combination."( Second-trimester abortion by extra-amniotic instillation of Rivanol combined with intravenous administration of oxytocin or prostaglandin F2 alpha.
Hamberger, L; Klinte, I; Wiqvist, N, 1983
)
0.27
"Three-color fluorescence detection methods are described based upon covalently coupling the dye 2-methoxy-2,4-diphenyl-2(2H)-furanone (MDPF) to proteins immobilized on poly(vinylidene difluoride) (PVDF) membranes, followed by detection of target proteins using alkaline-phosphatase-conjugated reporter molecules in combination with the fluorogenic substrate 9H-(1,3-dichloro-9,9-dimethylacridin-2-one-7-yl) phosphate (DDAO-phosphate) as well as horseradish peroxidase-conjugated reporter molecules in combination with the new fluorogenic substrate Amplex Gold reagent."( Simultaneous trichromatic fluorescence detection of proteins on Western blots using an amine-reactive dye in combination with alkaline phosphatase- and horseradish peroxidase-antibody conjugates.
Hart, C; Leung, WY; Liu, J; Martin, K; Patton, WF, 2003
)
0.32
" We performed a phase 1 study with escalating doses of GF120918 in combination with doxorubicin."( A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
de Boer-Dennert, M; de Leeuw, K; Jewell, RC; Luyten, GP; Paul, EM; Planting, AS; Purvis, NB; Sonneveld, P; Sparreboom, A; van der Burg, ME; van der Gaast, A; Verweij, J; Wissel, PS, 2005
)
0.33
" The target steady-state plasma level for GF120918 was exceeded in 12 out of 19 patients who received 400 mg GF120918 alone twice daily and in 12 of 17 patients who received 400 mg GF120918 twice daily in combination with doxorubicin."( A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
de Boer-Dennert, M; de Leeuw, K; Jewell, RC; Luyten, GP; Paul, EM; Planting, AS; Purvis, NB; Sonneveld, P; Sparreboom, A; van der Burg, ME; van der Gaast, A; Verweij, J; Wissel, PS, 2005
)
0.33
" A doxorubicin dose of 60 mg/m2 on day 3 in combination with 400 mg GF120918 twice daily on days 1-5 is an acceptable regimen for further clinical trials."( A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
de Boer-Dennert, M; de Leeuw, K; Jewell, RC; Luyten, GP; Paul, EM; Planting, AS; Purvis, NB; Sonneveld, P; Sparreboom, A; van der Burg, ME; van der Gaast, A; Verweij, J; Wissel, PS, 2005
)
0.33
"Because modulation of P-glycoprotein (Pgp) through inhibition or induction can lead to drug-drug interactions by altering intestinal, central nervous system, renal, or biliary efflux, it is anticipated that information regarding the potential interaction of drug candidates with Pgp will be a future regulatory expectation."( In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.
Balakrishnan, A; Humphreys, JE; Keogh, JP; Kunta, JR; Polli, JW; Rautio, J; Serabjit-Singh, CJ; Webster, LO, 2006
)
0.33
" Its dynamics and disturbances during standard therapy combined with cycloferon were clarified."( [Dynamics of interferon status in patients with atopic dermatitis during standard therapy combined with cycloferon].
Gevorkian, OV; Manakhova, LS; Ospel'nikova, TP; Smirnova, TD, 2011
)
0.37
"The efficiency of modern immunoactive preparation cycloferon at coplex therapy of the patients with nonalcoholic steatohepatitis (NASH) combined with irritable bowel syndrome (IBS)."( [Efficiency of modern immunoactive preparation cycloferon at coplex therapy of the patients with nonalcoholic steatohepatitis combined with irritable bowel syndrome].
Frolov, VM; Kruhlova, OV; Sotskaia, IaA; Tereshin, VA,
)
0.13
"Rodent models are less suitable for predicting drug-drug interactions at the level of the human intestinal mucosa, especially when nuclear receptors such as pregnane X receptor (PXR) are involved."( PXR/CYP3A4-humanized mice for studying drug-drug interactions involving intestinal P-glycoprotein.
Annaert, P; Augustijns, P; Baes, M; Gonzalez, FJ; Holmstock, N, 2013
)
0.39
"PET-CT imaging with [(18)F]-gefitinib is a powerful tool to non-invasively assess potential ABCB1- and ABCG2-mediated drug-drug interactions (DDIs) in vivo."( PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
DeGroot, J; Jansen, HT; Kivits, S; Läppchen, T; Sio, CF; Steinbach, OC; van de Steeg, E; van der Hoorn, JW; van Driel, A; Vlaming, ML, 2015
)
0.42
" In other words, the tissue distribution of drugs can be influenced by drug-drug interaction (DDI) at efflux transporters in certain tissues (local DDI) without any apparent change in plasma concentration (systemic DDI)."( Local Drug-Drug Interaction of Donepezil with Cilostazol at Breast Cancer Resistance Protein (ABCG2) Increases Drug Accumulation in Heart.
Nakanishi, T; Shinozaki, K; Takeuchi, R; Tamai, I, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" The nature of the salt associated to the active principle can give some advantages in the field of activity, bioavailability and toxicity."( Plasmodium berghei mouse model: antimalarial activity of new alkaloid salts and of thiosemicarbazone and acridine derivatives.
Loiseau, PM; Nguyen, DX, 1996
)
0.29
" To avoid the confounding drug transport provided by P-glycoprotein (P-gp), the roles of Bcrp1 in the bioavailability of topotecan and the effect of GF120918 were studied in both wild-type and P-gp-deficient mice and their fetuses."( Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Beijnen, JH; Brinkhuis, RF; Jonker, JW; Maliepaard, M; Schellens, JH; Schinkel, AH; Smit, JW, 2000
)
0.31
" When both topotecan and GF120918 were administered orally, the bioavailability (i."( Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Beijnen, JH; Brinkhuis, RF; Jonker, JW; Maliepaard, M; Schellens, JH; Schinkel, AH; Smit, JW, 2000
)
0.31
"Previous studies in mice with disrupted mdr1a P-glycoprotein genes have shown that the oral bioavailability of paclitaxel is very low because of the presence of this drug-transporting protein in the intestinal wall."( Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
Bardelmeijer, HA; Beijnen, JH; Brouwer, KR; Nooijen, WJ; Rosing, H; Schellens, JH; van Tellingen, O, 2000
)
0.31
"Oral bioavailability of paclitaxel is very low, which is due to efficient transport of the drug by the intestinal drug efflux pump P-glycoprotein (P-gp)."( Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.
Beijnen, JH; Jewell, RC; Koopman, FJ; Malingré, MM; Paul, EM; Rosing, H; Schellens, JH; Ten Bokkel Huinink, WW, 2001
)
0.31
"Drug efflux by intestinal P-glycoprotein (P-gp) is known to decrease the oral bioavailability of many CYP3A4 substrates."( Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.
Benet, LZ; Cummins, CL; Jacobsen, W, 2002
)
0.31
"We discovered that breast cancer resistance protein (BCRP), a recently identified adenosine triphosphate-binding cassette drug transporter, substantially limits the oral bioavailability of topotecan in mdr1a/1b(-/-) P-glycoprotein (P-gp) knockout and wild-type mice."( Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
Beijnen, JH; Jewell, RC; Kruijtzer, CM; Paul, EM; Rosing, H; Schellens, JH; Schot, M; ten Bokkel Huinink, WW, 2002
)
0.31
" The apparent bioavailability in this cohort increased significantly from 40."( Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
Beijnen, JH; Jewell, RC; Kruijtzer, CM; Paul, EM; Rosing, H; Schellens, JH; Schot, M; ten Bokkel Huinink, WW, 2002
)
0.31
" The apparent oral bioavailability increased from 40."( Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
Beijnen, JH; Jewell, RC; Kruijtzer, CM; Paul, EM; Rosing, H; Schellens, JH; Schot, M; ten Bokkel Huinink, WW, 2002
)
0.31
"P-glycoprotein inhibitors can increase the oral bioavailability of paclitaxel."( Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice.
Bardelmeijer, HA; Beijnen, JH; Ouwehand, M; Schellens, JH; van Tellingen, O, 2004
)
0.32
" GV196771 has low oral bioavailability (<10%) and plasma clearance ( approximately 2 ml/min/kg) in rats."( The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters.
Barnaby, RJ; Baughman, TM; Bertolotti, L; Humphreys, JE; Jordan, KH; Mote, AL; Polli, JW; Read, KD; Serabjit-Singh, CJ; Vitulli, G; Webster, LO, 2004
)
0.32
" This method was successfully applied to support the pharmacokinetics of a clinical trial in which orally applied Elacridar was used as a bioavailability enhancer."( Quantitative analysis of the P-glycoprotein inhibitor Elacridar (GF120918) in human and dog plasma using liquid chromatography with tandem mass spectrometric detection.
Beijnen, JH; Causon, RC; Rosing, H; Schellens, JH; Stokvis, E, 2004
)
0.32
" Coadministration of 50 mg/kg GF120918 [N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9, 10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide] with 2 mg/kg topotecan significantly increased the area under the plasma concentration-time curve and bioavailability of topotecan by more than 4-fold in these animals, indicating the importance of BCRP in the bioavailability and disposition of topotecan in rats."( Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
Morris, ME; Sagawa, K; Wang, X; Zhang, S, 2005
)
0.33
" This points to flavonoid-mediated stimulation of the bioavailability of PhIP and, thus, a possible adverse effect of these supposed beneficial food ingredients."( An in vitro and in silico study on the flavonoid-mediated modulation of the transport of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) through Caco-2 monolayers.
Alink, GM; Freidig, AP; Groten, JP; Rietjens, IM; Schutte, ME; van de Sandt, JJ, 2006
)
0.33
" ABCG2 also appears influential in the inter-patient variation and generally poor oral bioavailability of certain chemotherapeutic drugs such as topotecan."( The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2).
Hardwick, LJ; van Veen, HW; Velamakanni, S, 2007
)
0.34
"The bioavailability and targeted distribution of abacavir (ABC) and zidovudine (AZT) to viral reservoirs may be influenced by efflux transporters."( Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine.
Elmquist, WF; Giri, N; Pan, G, 2007
)
0.34
"Breast cancer resistance protein (ABCG2) substantially limits the oral bioavailability of topotecan."( A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients.
Beijnen, JH; Jewell, RC; Kuppens, IE; Mangum, SG; Paul, EM; Radema, SA; Schellens, JH; Voest, EE; Witteveen, EO, 2007
)
0.34
"The poor oral bioavailability of the opioid receptor antagonist naloxone (NA) when compared with naltrexone (NX) may be related to a greater interaction of naloxone with the efflux drug transporter P-glycoprotein (P-gp)."( P-glycoprotein is not involved in the differential oral potency of naloxone and naltrexone.
Daali, Y; Dayer, P; Desmeules, J; Kanaan, M, 2009
)
0.35
" The ATP-binding cassette efflux transporter, breast cancer resistance protein (Bcrp, Abcg2), is involved in the transport of quercetin and represents a possible mechanism for the low bioavailability of quercetin."( The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux.
An, G; Gallegos, J; Morris, ME, 2011
)
0.37
" Here we assessed factors that may influence its oral bioavailability in rats."( Pharmacokinetic modeling to assess factors affecting the oral bioavailability of the lactone and carboxylate forms of the lipophilic camptothecin analogue AR-67 in rats.
Adane, ED; Anderson, BD; Leggas, M; Liu, Z; Xiang, TX, 2012
)
0.38
" A population PK model that simultaneously fitted to oral and intravenous data was used to estimate the bioavailability (F) and clearance of AR-67."( Pharmacokinetic modeling to assess factors affecting the oral bioavailability of the lactone and carboxylate forms of the lipophilic camptothecin analogue AR-67 in rats.
Adane, ED; Anderson, BD; Leggas, M; Liu, Z; Xiang, TX, 2012
)
0.38
" Covariate analysis showed that the bioavailability of the lactone, but not its clearance, was dose dependent."( Pharmacokinetic modeling to assess factors affecting the oral bioavailability of the lactone and carboxylate forms of the lipophilic camptothecin analogue AR-67 in rats.
Adane, ED; Anderson, BD; Leggas, M; Liu, Z; Xiang, TX, 2012
)
0.38
"The objective of this study was to determine the bioavailability and disposition of elacridar (GF120918; N-(4-(2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl)phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide) in plasma and brain after various routes of administration in the mouse."( Brain distribution and bioavailability of elacridar after different routes of administration in the mouse.
Agarwal, S; Elmquist, WF; Sane, R, 2012
)
0.38
" Friend Leukemia Virus Strain B (FVB) mice were used to determine the bioavailability of elacridar after a 10 mg/kg dose of elacridar in the microemulsion, intraperitoneally (i."( Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.
Elmquist, WF; Mittapalli, RK; Sane, R, 2013
)
0.39
" The resulting low oral bioavailability can be boosted by co-administration of P-gp or CYP3A4 inhibitors."( Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation.
Beijnen, JH; Hendrikx, JJ; Lagas, JS; Rosing, H; Schellens, JH; Schinkel, AH; Wagenaar, E, 2014
)
0.4
"In mice, the bioavailability changes, which corrected the effect of systemic clearance by Bcrp knockout, correlated well with the AUC changes in humans, whereas the correlation was weak when AUC changes were directly compared."( Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates.
Abe, K; Hagihara-Nakagomi, R; Hirouchi, M; Imaoka, T; Izumi, T; Karibe, T; Mikkaichi, T; Okudaira, N; Watanabe, N; Yasuda, S, 2015
)
0.42
"This study suggests that pharmacokinetics studies that use the correction of the bioavailability changes in Bcrp knockout mice are effective for estimating clinical AUC changes in ABCG2 421C>A variants for BCRP substrate drugs and those studies in monkeys that use a BCRP inhibitor serve for the assessment of BCRP impact on the gastrointestinal absorption in a non-rodent model."( Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates.
Abe, K; Hagihara-Nakagomi, R; Hirouchi, M; Imaoka, T; Izumi, T; Karibe, T; Mikkaichi, T; Okudaira, N; Watanabe, N; Yasuda, S, 2015
)
0.42
" As pH is an essential and sensitive factor in various biological processes, a simple yet reliable pH-sensitive model such as is demonstrated here can have promising applications in the host-assisted delivery of prodrug to the target sites, such as cancer or tumour microenvironments, with an enhanced stability, bioavailability and activity, and also in the design of new fluorescent probes, sensors and smart materials for applications in nano-science."( pH-Assisted control over the binding and relocation of an acridine guest between a macrocyclic nanocarrier and natural DNA.
Pal, H; Sayed, M, 2015
)
0.42
" Despite its lower bioavailability and higher clearance, as compared to nepicastat, etamicastat showed preferential distribution to peripheral tissues and high plasma free fraction (15."( Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat.
Bonifácio, MJ; Fernandes-Lopes, C; Igreja, B; Loureiro, AI; Pires, N; Soares-da-Silva, P; Wright, LC, 2015
)
0.42
" Taken together, our findings demonstrate that vemurafenib is unlikely to exhibit a clinically significant interaction with CYP3A4, but that modulation of bioavailability through PXR-mediated regulation of drug transporters (e."( Activation status of the pregnane X receptor influences vemurafenib availability in humanized mouse models.
Henderson, CJ; MacLeod, AK; McLaughlin, LA; Wolf, CR, 2015
)
0.42
"Elacridar is highly demanded for proof-of-concept clinical trials that study the drug's suitability to boost brain penetration and bioavailability of numerous anticancer agents."( Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies.
Beijnen, JH; Nuijen, B; Sawicki, E; Schellens, JH, 2017
)
0.46
" In some instances, either low oral bioavailability or lack of brain penetration has been attributed to P-gp mediated efflux activity."( Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies.
Dash, RP; Jayachandra Babu, R; Srinivas, NR, 2017
)
0.46
"Lipid-based drug delivery systems, a well-tolerated class of formulations, have been evaluated extensively to enhance the bioavailability of poorly soluble drugs."( Incorporation of lipolysis in monolayer permeability studies of lipid-based oral drug delivery systems.
Layek, B; Prabha, S; Sadhukha, T, 2018
)
0.48
"This study was designed to investigate the effects of P-glycoprotein (P-gp) expressed in the intestine on the nonlinear pharmacokinetics (PK) of T-3256336, an inhibitor of apoptosis protein inhibitor, and food effects on its bioavailability in rats."( Impact of P-Glycoprotein on Intestinal Absorption of an Inhibitor of Apoptosis Protein Antagonist in Rats: Mechanisms of Nonlinear Pharmacokinetics and Food Effects.
Hirabayashi, H; Kosugi, Y; Moriwaki, T; Yamamoto, S, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" The LD50 for BALB/c mice with single intraperitoneal dosage is approximately 25 mg/kg."( Antiviral activities of 4'-(9-acridinylamino)-methanesulfon-M-aniside (SN11841).
Byrd, DM, 1977
)
0.26
" Hydralazine can be determined in dosage forms that also contain varying quantities of reserpine and hydrochlorothiazide."( Colorimetric determination of hydralazine with 9-chloroacridine.
Chang, YC; Stewart, JT, 1979
)
0.26
" The method was applied to the analysis of isoniazid in pharmaceutical dosage forms and found to be comparable to the USP XVIII assay."( Colorimetric determination of isoniazid with 9-chloroacridine.
Settle, DA; Stewart, JT, 1975
)
0.25
" The monotherapy with the applied amino acids in the same dosage showed no tumor inhibition."( Potentiated chemotherapeutic activity of 3,6-diamino-10-methyl-acridinium by combination with glycine or DL-alpha-alanine on the Ehrlich carcinoma.
Osswald, H, 1975
)
0.25
"The effect of Ro 15-5458 (10-2-(diethylamino)ethyl-9-acridanone(2-thiazolin- 2-yl)hydrazone) on the steady-state RNA levels of Schistosoma mansoni was studied after dosing the host with 15 mg kg-1 and retrieving parasites."( The schistosomicidal compound Ro 15-5458 causes a reduction in the RNA content of Schistosoma mansoni.
Bennett, JL; Eshete, F, 1991
)
0.28
"We evaluated a variety of biochemical parameters in Schistosoma mansoni isolated from mice up to 4 days after dosing with 15 mg/kg Ro 15-5458."( Schistosoma mansoni: biochemical characteristics of the antischistosomal effects of Ro 15-5458.
Bennett, JL; Eshete, F, 1990
)
0.28
" The procedure is sufficiently sensitive, precise, and accurate for the determination of cycloserine in its dosage form."( Spectrophotometric determination of cycloserine with 9-methoxyacridine.
Stewart, JT; Yoo, GS, 1988
)
0.27
"064 kC/kg (2-8 MR] acrinol on liquid dosage form have been carried out to study the application of radiosterilization."( [Radiolysis and variation of anti-microbial activity of gamma-irradiated acrinol aqueous solution on radiosterilization].
Amasaki, C; Ikeda, N; Kanbashi, T; Kimura, S; Shitano, N; Taimatsu, M, 1987
)
0.27
" Dose-response relationships were obtained for DBa,hAC as well as for BaP."( Experimental studies on the carcinogenicity of five nitrogen containing polycyclic aromatic compounds directly injected into rat lungs.
Brune, H; Deutsch-Wenzel, RP; Grimmer, G, 1983
)
0.27
" A dose-response relation exists such that the number and severity of abnormalities increase with increasing concentration of the teratogen."( Chemical impurity produces extra compound eyes and heads in crickets.
Walton, BT, 1981
)
0.26
" Via intratracheal instillation, male CD rats (6/group) were dosed 3 times with BA, DBA, DBP or DBAC in a 24-h interval."( Induction of in vivo DNA adducts by 4 industrial by-products in the rat-lung-cell system.
Cutler, D; Ong, T; Stewart, JD; Whong, WZ, 1994
)
0.29
" Dose-response curves were generated for two modulators of Pgp function, GG918 and PSC833."( In vitro comparison of sestamibi, tetrofosmin, and furifosmin as agents for functional imaging of multidrug resistance in tumors.
Ballinger, JR; Moore, MJ; Muzzammil, T, 2000
)
0.31
" dosing of paclitaxel, respectively."( Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
Bardelmeijer, HA; Beijnen, JH; Brouwer, KR; Nooijen, WJ; Rosing, H; Schellens, JH; van Tellingen, O, 2000
)
0.31
" To demonstrate the tandem luminescence concept in a model assay system, dose-response curves for two analytes, biotinylated BSA and myoglobin, were generated using a competitive binding format."( Dual analyte detection using tandem flash luminescence.
Adamczyk, M; Moore, JA; Shreder, K, 2002
)
0.31
" Both laboratories found genotoxicity with a positive dose-response relationship for maleic hydrazide and acridine."( Genotoxicity of maleic hydrazide, acridine and DEHP in Allium cepa root cells performed by two different laboratories.
Lopez, LC; Moretton, J; Nielsen, MH; Rank, J, 2002
)
0.31
" Including GF120918 in a multiple (twice daily) dosing regimen, we found continued accumulation of saquinavir in brain over several days, resulting in 10-fold higher levels compared with vehicle-treated mice."( Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir.
Beijnen, JH; Huisman, MT; Schinkel, AH; Smit, JW; Wiltshire, HR, 2003
)
0.32
" The dose-response for choline (0-50 microM) was established in buffer and was applicable to the quantification of choline in human plasma."( Rapid high-throughput detection of peroxide with an acridinium-9-carboxamide: a homogeneous chemiluminescent assay for plasma choline.
Adamczyk, M; Brashear, RJ; Mattingly, PG, 2006
)
0.33
" The results demonstrate that the preparation of dosage forms and their storage conditions will have an important influence on the stability--and hence biological efficacy--of BRACO19 and related substances."( Decomposition of the telomere-targeting agent BRACO19 in physiological media results in products with decreased inhibitory potential.
Baldes, C; Boettcher, S; Kleideiter, E; Klotz, U; Lehr, CM; Mürdter, TE; Piotrowska, K; Schaefer, UF; Taetz, S; Zapp, J, 2008
)
0.35
" administration, whereas the AUC after oral dosing was unaltered."( The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.
Beijnen, JH; Buckle, T; Oostendorp, RL; Schellens, JH; van Tellingen, O, 2009
)
0.35
" The aim of this study was to evaluate the dose-response relationship of two potent P-gp inhibitors and to investigate if increased brain uptake of VPM mediated by P-gp inhibition can be used to assess regional differences in P-gp activity."( Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
Bankstahl, JP; Bankstahl, M; Brauner, R; Ding, X; Karch, R; Kuntner, C; Langer, O; Löscher, W; Meier, M; Müller, M; Stanek, J; Stundner, G; Wanek, T, 2010
)
0.36
" Polyacridine PEG-peptide DNA open polyplexes were dosed intramuscularly and electroporated in mice to demonstrate their functional activity in gene transfer."( Discovery of metabolically stabilized electronegative polyacridine-PEG peptide DNA open polyplexes.
Anderson, K; Baumhover, NJ; Fernandez, CA; Rice, KG, 2010
)
0.36
" A tail vein dose of PEGylated polyacridine peptide pGL3 polyplexes (1 μg in 50 μl), followed by a stimulatory hydrodynamic dose of normal saline at times ranging from 5 to 60 min post-DNA administration, led to a high level of luciferase expression in the liver, equivalent to levels mediated by direct hydrodynamic dosing of 1 μg of pGL3."( Metabolically stabilized long-circulating PEGylated polyacridine peptide polyplexes mediate hydrodynamically stimulated gene expression in liver.
Baumhover, NJ; Duskey, JT; Ericson, MD; Fernandez, CA; Khargharia, S; Kizzire, K; Rice, KG, 2011
)
0.37
" In vivo, the systemic exposure of sunitinib after oral dosing (10 mg kg(-1) ) was unchanged when muABCB1 and/or muABCG2 were absent."( Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
Beijnen, JH; Hillebrand, MJ; Lagas, JS; Lankheet, NA; Poller, B; Rosing, H; Schinkel, AH; Tang, SC, 2012
)
0.38
"Camptothecin analogues are anticancer drugs effective when dosed in protracted schedules."( Pharmacokinetic modeling to assess factors affecting the oral bioavailability of the lactone and carboxylate forms of the lipophilic camptothecin analogue AR-67 in rats.
Adane, ED; Anderson, BD; Leggas, M; Liu, Z; Xiang, TX, 2012
)
0.38
" In vivo, the systemic exposure of N-desethyl sunitinib after oral dosing of sunitinib malate (10 mg/kg) was unchanged when Abcb1 and/or Abcg2 were absent."( P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.
Beijnen, JH; Lankheet, NA; Poller, B; Schinkel, AH; Tang, SC; Wagenaar, E, 2012
)
0.38
" We previously demonstrated that acridine-modified lysine (Acr) in (Acr-Lys)(6)-Cys-PEG(5kDa) stabilizes a 1-μg pGL3 dose for up to 1 h in the circulation, resulting in HD-stimulated (saline only) gene expression in the liver, equivalent in magnitude to direct-HD dosing of 1 μg of pGL3."( High-affinity PEGylated polyacridine peptide polyplexes mediate potent in vivo gene expression.
Khargharia, S; Kizzire, K; Rice, KG, 2013
)
0.39
" Glioma-bearing mice were orally dosed with dasatinib, a kinase inhibitor and dual BCRP/PgP substrate that is being currently tested in clinical trials."( Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents.
Agarwal, S; Decker, SA; Donelson, R; Elmquist, WF; Gallardo, JL; Mittapalli, RK; Ohlfest, JR; Pokorny, JL; Santacruz, KS; Sarkaria, JN; Seiler, C; Zellmer, DM, 2012
)
0.38
" The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with GF-120918, a dual BCRP and P-gp inhibitor)."( Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats.
Frost, CE; Goosen, TC; He, K; Humphreys, WG; Rodrigues, AD; Wang, L; Wang, X; Zhang, D, 2013
)
0.39
" These results demonstrate that efflux transport in the BBB is involved in limiting the brain distribution of palbociclib and this has critical implications in determining effective dosing regimens of palbociclib therapy in the treatment of brain tumors."( Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model.
Bakken, K; Elmquist, WF; Mittapalli, RK; Parrish, KE; Pokorny, J; Sarkaria, JN, 2015
)
0.42
" However, it has been difficult to predict the in vivo performance of lipid dosage forms based on conventional in vitro techniques such as cell monolayer permeability studies because of the complexity of the gastrointestinal processing of lipid formulations."( Incorporation of lipolysis in monolayer permeability studies of lipid-based oral drug delivery systems.
Layek, B; Prabha, S; Sadhukha, T, 2018
)
0.48
" The chemical inhibitor was dosed intravenously via the femoral artery, and a cassette of known substrates was infused via the jugular vein."( Optimization of dose and route of administration of the P-glycoprotein inhibitor, valspodar (PSC-833) and the P-glycoprotein and breast cancer resistance protein dual-inhibitor, elacridar (GF120918) as dual infusion in rats.
Grater, R; Kapadnis, S; Pietrasiewicz, A; Qiu, D; Rowbottom, C; Trapa, P; Tuczewycz, T, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
genotoxinA role played by a chemical compound to induce direct or indirect DNA damage. Such damage can potentially lead to the formation of a malignant tumour, but DNA damage does not lead inevitably to the creation of cancerous cells.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
mancude organic heterotricyclic parent
polycyclic heteroarene
acridines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency50.11875.623417.292931.6228AID485281
thioredoxin reductaseRattus norvegicus (Norway rat)Potency79.43280.100020.879379.4328AID588456
TDP1 proteinHomo sapiens (human)Potency11.29470.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency10.00000.180013.557439.8107AID1460
Smad3Homo sapiens (human)Potency22.38720.00527.809829.0929AID588855
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency35.48130.011212.4002100.0000AID1030
alpha-galactosidaseHomo sapiens (human)Potency14.12544.466818.391635.4813AID2107
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency15.84890.001815.663839.8107AID894
flap endonuclease 1Homo sapiens (human)Potency56.23410.133725.412989.1251AID588795
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency31.62280.050127.073689.1251AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)6.84000.00000.933210.0000AID1690841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA topoisomerase 2-alphaHomo sapiens (human)Activity1,000.00008.50008.50008.5000AID1434039
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (30)

Processvia Protein(s)Taxonomy
hematopoietic progenitor cell differentiationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topological changeDNA topoisomerase 2-alphaHomo sapiens (human)
DNA ligationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA damage responseDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome segregationDNA topoisomerase 2-alphaHomo sapiens (human)
female meiotic nuclear divisionDNA topoisomerase 2-alphaHomo sapiens (human)
apoptotic chromosome condensationDNA topoisomerase 2-alphaHomo sapiens (human)
embryonic cleavageDNA topoisomerase 2-alphaHomo sapiens (human)
regulation of circadian rhythmDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of apoptotic processDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediateDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA topoisomerase 2-alphaHomo sapiens (human)
rhythmic processDNA topoisomerase 2-alphaHomo sapiens (human)
negative regulation of DNA duplex unwindingDNA topoisomerase 2-alphaHomo sapiens (human)
resolution of meiotic recombination intermediatesDNA topoisomerase 2-alphaHomo sapiens (human)
sister chromatid segregationDNA topoisomerase 2-alphaHomo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
magnesium ion bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
chromatin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
RNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 2-alphaHomo sapiens (human)
protein kinase C bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP-dependent activity, acting on DNADNA topoisomerase 2-alphaHomo sapiens (human)
DNA binding, bendingDNA topoisomerase 2-alphaHomo sapiens (human)
protein homodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
ubiquitin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein heterodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (24)

Processvia Protein(s)Taxonomy
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
nuclear chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
centrioleDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome, centromeric regionDNA topoisomerase 2-alphaHomo sapiens (human)
condensed chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
male germ cell nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
cytoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complexDNA topoisomerase 2-alphaHomo sapiens (human)
protein-containing complexDNA topoisomerase 2-alphaHomo sapiens (human)
ribonucleoprotein complexDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (43)

Assay IDTitleYearJournalArticle
AID310933Permeability across PAMPA membrane after 7 hrs2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID375070Displacement of gentamycin from RNA bulge site of Escherichia coli 16S ribosomal 27-nucleotide A-site RNA by T2 filter NMR spectroscopy based competitive binding assay2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Design and implementation of an ribonucleic acid (RNA) directed fragment library.
AID55630Induced change in DNA-melting (deltaTm) with [poly(dA-dT)]2 at pH 65.01995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID55304Inhibitory concentration against DNA-bound ethidium for cytotoxicity1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID1145386Partition coefficient, log P of the compound by shake-flask technique1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Direct measurement of octanol-water partition coefficients by high-pressure liquid chromatography.
AID54988Change in DNA-melting (deltaTm) with calf thymus DNA at pH 65.01995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID55500Concentration required to give 50% fluorescence quenching of bound ethidium for [ethidium]: [poly(dA-dT)]2 DNA in ratio of 0.1:1 at pH 51997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID23973Partition coefficient (logD, measured by HPLC, log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID375067Displacement of gentamycin from RNA bulge site of Escherichia coli 16S ribosomal 27-nucleotide A-site RNA by water Logsy NMR spectroscopy based noncompetitive binding assay2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Design and implementation of an ribonucleic acid (RNA) directed fragment library.
AID23970logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID54990Change in DNA-melting (deltaTm) with calf thymus DNA at pH 7.01995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID1145387Partition coefficient, log P of the compound by HPLC analysis1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Direct measurement of octanol-water partition coefficients by high-pressure liquid chromatography.
AID225777Inhibitory concentration against ethidium in DNA-binding assay with [poly(dA-dT)]2 (synthetic oligonucleotide)1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID420787Antagonist activity at human 5HT3A receptor expressed in HEK293 cells assessed as inhibition of serotonin-induced inward Na+ current at >= 10 uM2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Molecular properties of psychopharmacological drugs determining non-competitive inhibition of 5-HT3A receptors.
AID23959logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID23965logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1434039Poison activity at recombinant human topoisomerase-2alpha expressed in Saccharomyces cerevisiae JEL1 harboring topoisomerase1 deletion mutant assessed as concentration required to triple the level of DNA cleavage complex relative to basal level using supe2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Novel trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-ones act as covalent poisons of human topoisomerase IIα.
AID310931Partition coefficient, log P of the compound2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID10004Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID98558Concentration required to inhibit the cell growth by 50 % after 48 hr in L1210 leukemic cells.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID54658Inhibitory concentration against ethidium in DNA-binding assay1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID26296Partition coefficient (logD7.4)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID23971logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID733186Binding affinity to calf thymus DNA up to 5 mM2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Synthesis and biological evaluation of new cytotoxic indazolo[4,3-gh]isoquinolinone derivatives.
AID28956Partition coefficient (logP) (dodecane)2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Rational determination of transfer free energies of small drugs across the water-oil interface.
AID220346Drug concentration required to produce 50% inhibition of fluorescence bound ethidium to CT-DNA (1.26:1) (+/-SEM 5%)2002Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23
Effect of spermine conjugation on the cytotoxicity and cellular transport of acridine.
AID46135Inhibitory concentration against ethidium:Calf thymus DNA (1.26:1) binding at pH 71997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID375072Binding affinity to Escherichia coli 16S ribosomal 27-nucleotide A-site RNA by ID imino spectrum based NMR spectroscopy2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Design and implementation of an ribonucleic acid (RNA) directed fragment library.
AID225778Inhibitory concentration against ethidium in DNA-binding assay with [poly(dG-dC)]2 (synthetic oligonucleotide)1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID98563Cytotoxic potency required to inhibit L1210 cell growth by 50% after cell drug contact for 48 hrs1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID28957Partition coefficient (logP)2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Rational determination of transfer free energies of small drugs across the water-oil interface.
AID55632Induced change in DNA-melting (deltaTm) with [poly(dG-dC)]2 at pH 65.01995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID46169Inhibitory concentration against ethidium:Calf thymus DNA(0.1:1) binding at pH 51997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID46133Inhibitory concentration against ethidium:calf thymus DNA (1.26:1) binding at pH 51997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID1690841Inhibition of recombinant human C-terminal 6His-tagged AChE (Glu32 to Leu614 residues) expressed in CHO cells using acetylthiocholine iodide as substrate preincubated for 5 mins measured after 15 mins by DTNB reagent based assay2020European journal of medicinal chemistry, Apr-15, Volume: 192Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease.
AID55499Concentration required to give 50% fluorescence quenching of bound ethidium for [ethidium]: [(poly dG-dC)]2 DNA in ratio of 0.1:1 at pH 51997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID23968logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID23963logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID23961logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID10007Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6,446)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903976 (61.68)18.7374
1990's588 (9.12)18.2507
2000's912 (14.15)29.6817
2010's819 (12.71)24.3611
2020's151 (2.34)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 58.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index58.52 (24.57)
Research Supply Index8.88 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index103.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (58.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials169 (2.42%)5.53%
Reviews228 (3.26%)6.00%
Case Studies26 (0.37%)4.05%
Observational0 (0.00%)0.25%
Other6,564 (93.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]